Recursion Pharmaceuticals Inc (RXRX)

Currency in USD
3.50
-0.38(-9.79%)
Closed·
3.53+0.03(+0.86%)
·

RXRX Earnings

Latest Release
Nov 02, 2026
EPS / Forecast
-0.22 / -0.22
Revenue / Forecast
18.55M / 12.98M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
12/2026--/-0.216--/13.74M----Free Sign Up
09/2026-0.220/-0.22018.55M/12.98M0%+42.91%Free Sign Up
06/2026-0.250/-0.2407.67M/12.15M-4.17%-36.87%Free Sign Up
03/2026-0.220/-0.2606.47M/16.28M+15.38%-60.26%Free Sign Up
12/2025-0.210/-0.30035.54M/24.51M+30%+45%Free Sign Up
09/2025-0.360/-0.3705.18M/16.95M+2.7%-69.44%Free Sign Up
06/2025-0.410/-0.35019.10M/15.37M-17.14%+24.27%Free Sign Up
03/2025-0.500/-0.49014.82M/14.98M-2.04%-1.07%Free Sign Up
12/2024-0.530/-0.4104.55M/13.40M-29.27%-66.04%Free Sign Up
09/2024-0.340/-0.33026.10M/12.62M-3.03%+106.81%Free Sign Up

All numbers in USD

Recursion Pharmaceuticals Inc Earnings Call Summary for Q3/2026

  • Q3 revenue of $18.55M beat forecasts by 42.9%; adjusted EPS of -$0.22 matched estimates as shares rose 3.1% to $3.95 after-hours.
  • Company extended cash runway into 2029, lowered 2026 operating expense guidance to below $375M from $390M; 2027 guidance set below $360M.
  • Recursion reported $535M+ in cumulative partner cash inflows since inception, including $100M+ in milestones over past 24 months.
  • Phase III study for REC-4881 in familial adenomatous polyposis targeted for H2 2027; REC-1245 endometrial cancer data expected same period.
  • CEO emphasized AI-driven platform repeatability, claiming 80-90% fewer compounds synthesized vs. industry benchmarks and 30-60% faster enrollment.
Last Updated: 03/11/2026, 15:58
Read Full Transcript

FAQ

What Is Recursion Pharmaceuticals's Earnings Per Share (TTM)?

The Recursion Pharmaceuticals EPS (TTM) is -0.89.

When Is The Next Recursion Pharmaceuticals Earnings Date?

Recursion Pharmaceuticals will release its next earnings report on Mar 03, 2027.

What Is Recursion Pharmaceuticals’s Revenue Forecasts For Upcoming Quarters?

Recursion Pharmaceuticals’s revenue forecast is 13.74M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.